[{"orgOrder":0,"company":"GATC Health","sponsor":"Lisata Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Oncology","graph2":"Phase II","graph3":"GATC Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GATC Health \/ Lisata Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"GATC Health \/ Lisata Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by GATC Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          German Wound Congress
                          Not Confirmed
                          German Wound Congress
                          Not Confirmed

                          Details : GATC’s MAT AI platform will analyze Lisata’s investigational drug, LSTA1 (certepetide), to identify optimized and derisked development opportunities across various indications.

                          Product Name : LSTA1

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 05, 2025

                          Lead Product(s) : Certepetide,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Lisata Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank